Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - metaraminol tartrate, quantity: 9.488 mg (equivalent: metaraminol, qty 5 mg) - injection, solution - excipient ingredients: water for injections; dilute hydrochloric acid; sodium chloride - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia,adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma. ,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 785 microgram (equivalent: fentanyl, qty 500 microgram) - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - dexamethasone sodium phosphate, quantity: 8.74 mg (equivalent: dexamethasone phosphate, qty 8 mg) - injection, solution - excipient ingredients: sodium citrate; water for injections; disodium edetate; sodium hydroxide; creatinine - replacement therapy - adrenocortical insufficiency,dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in:,? acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy;,? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available;,? primary and secondary adrenocortical insufficiency.,disease therapy,dexamethasone is indicated for therapy of the following diseases:,collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy.,pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.,blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.,rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.,skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.,gastrointestinal disorders: ulcerative colitis, regional enteritis.,oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).,eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.,neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.,endocrine disorders: adrenal insufficiency.,preoperative and postoperative support,dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery.,shock,dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg (equivalent: dexamethasone phosphate, qty 4 mg) - injection, solution - excipient ingredients: disodium edetate; water for injections; sodium citrate; creatinine; sodium hydroxide - replacement therapy - adrenocortical insufficiency,dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in:,? acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy;,? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available;,? primary and secondary adrenocortical insufficiency.,disease therapy,dexamethasone is indicated for therapy of the following diseases:,collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy.,pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.,blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.,rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.,skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.,gastrointestinal disorders: ulcerative colitis, regional enteritis.,oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).,eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.,neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.,endocrine disorders: adrenal insufficiency.,preoperative and postoperative support,dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery.,shock,dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 150 mg/ml - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia. 2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 200 mg/ml - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia. 2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia.2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride, quantity: 75 mg/ml - injection, concentrated - excipient ingredients: water for injections - indications as at 04 november 2004 : 1.the treatment hypokalaemia. 2. treatment of digitalis intoxication. the iv route is indicated when the patient is unable to take potassium orally or if hypokalaemia is severe.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pethidine hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 18 may 2020: 1. the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. 2. pre-operative medication. 3. analgesic adjunct in general anaesthesia. 4. obstetric analgesia.